Treatments with Aβ1-42 have led to increased levels of axonal mRNA for AD-related genes like APP, ApoE, and CLU, suggesting their involvement in disease progression (Gao L. et al., 2022; Gao X. et al., 2022). This evidence concerns the gene APOE and Alzheimer disease.